What Forsteo Treats: Main Uses and Benefits

Forsteo is generally used across domains where additional symptomatic support is needed to address severe bone fragility, or osteoporosis, in patients determined to be at a high risk for fracture. The medication is relevant in conditions characterized by periods of heightened symptoms, including for postmenopausal women, men with certain forms of osteoporosis, and patients presenting with systemic or localized discomfort related to long-term steroid therapy. It is considered relevant in clinical settings that involve acute or unstable symptom patterns, particularly where prior symptomatic assistance may not have been appropriate or sufficient.

The medication is relevant for easing symptoms associated with acute or episodic changes, which includes the risk of major skeletal events such as vertebral (spine) and non-vertebral fractures. This supportive action contributes to easing the overall symptom load and helps maintain a sense of stability, assisting with maintaining functional stability.

“This medication contributes to reducing the incidence of new fractures and helps patients cope more steadily with symptom fluctuations associated with skeletal fragility.”

Forsteo (teriparatide) is a prescription medication used to treat certain patients with osteoporosis who are at a high risk of fracture. It works by stimulating new bone formation.

Who Can Use Forsteo

Forsteo is indicated for adults, including:

• Postmenopausal women with osteoporosis at increased risk of fracture.
• Men with primary or hypogonadal osteoporosis at increased risk of fracture.
• Men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.

Patients taking Forsteo should typically receive adequate supplemental calcium and vitamin D if their dietary intake is insufficient.

Who Cannot Use Forsteo (Contraindications)

Forsteo is generally contraindicated in individuals with specific pre-existing conditions. These include:

• Hypersensitivity to the active substance, teriparatide, or any excipients.
• Pre-existing hypercalcaemia (high blood calcium levels).
• Severe renal impairment.
• Metabolic bone diseases other than osteoporosis, such as Paget's disease or hyperparathyroidism.
• Unexplained high levels of alkaline phosphatase.
• Prior external beam or implant radiation therapy involving the skeleton.
• Skeletal malignancies or bone metastases.
• Pregnancy and breastfeeding. The medication should also not be used in children or young adults with open epiphyses (growing bones).

Interactions with other medicines and products

Official regulatory documents for Forsteo (teriparatide) primarily identify a potential pharmacodynamic interaction with specific cardiac medications. This section outlines officially documented interaction patterns and restrictions.

Documented Drug-Drug Interactions

This concern is formally described as a pharmacodynamic effect. Teriparatide causes a transient increase in serum calcium levels (hypercalcemia), and this increase may theoretically predispose patients taking digitalis preparations to toxicity. This is the main interaction cited in the regulatory prescribing information.

Pharmacokinetic and General Substance Interactions

Forsteo is a peptide and is cleared from the body primarily through non-enzymatic pathways. Consequently, official government labeling does not document clinically significant interactions based on the cytochrome P450 enzyme system or drug transporters. No restrictions are formally noted concerning interactions with food, alcohol, or herbal products. Pharmacodynamic studies also indicate that co-administration with hydrochlorothiazide or hormone replacement therapies like raloxifene did not result in clinically significant alterations to calcium levels or adverse events. The use of Forsteo is contraindicated in patients with severe renal impairment, which is a condition-based restriction that affects the overall risk profile.

Selective Activation of the PTH1 Receptor

The drug's active ingredient, teriparatide, functions as an agonist by binding to the Parathyroid Hormone 1 Receptor ( PTH1R) on osteoblasts (bone-forming cells) and osteocytes. This binding initiates specific intracellular signaling cascades, primarily activating the PKA pathway, which is responsible for the anabolic effects.

The Crucial Role of Intermittent Signaling

The resulting anabolic action is critically dependent on the drug's specific intermittent, pulsatile exposure pattern. This once-daily timing ensures that the PTH1R signal preferentially stimulates the proliferation and activity of bone-forming cells. This timing is key to shifting the bone remodeling cycle toward a net anabolic outcome, as opposed to the bone resorption that occurs under continuous PTH1R signaling.

Driving New Bone Formation (Anabolism) and Mineral Modulation

Activation of the PTH1R prevents osteoblast apoptosis and promotes their differentiation. This cellular cascade is further supported by the drug's effect on key regulators like sclerostin. The mechanism results in the deposition of new bone matrix, leading to a physiological increase in trabecular and cortical bone mass and an alteration in bone microarchitecture. Additionally, the mechanism transiently influences systemic mineral balance, causing a brief increase in serum calcium and decreased serum phosphate.

How to Use Forsteo (Teriparatide)

Forsteo (teriparatide) is a medication administered as a daily subcutaneous injection using a pre-filled pen device. Patients should receive proper training from a healthcare professional on the correct injection technique before initial use.

Dosage and Administration

Forsteo is a clear and colorless solution. It must be visually inspected for particulate matter or discoloration before administration; the pen should not be used if the liquid is cloudy, colored, or contains solid particles.

Important Considerations

• Initial Dose: The first few doses should be administered under circumstances where the patient can sit or lie down, as transient episodes of orthostatic hypotension (a form of low blood pressure upon standing) may occur shortly after injection.
• Storage: The pre-filled pen must be stored in a refrigerator (between 2°C and 8°C or 36°F and 46°F) and must not be frozen. The pen should be discarded 28 days after the first injection, even if some medication remains.
• Supplements: Patients are usually instructed to take supplemental calcium and vitamin D if their daily dietary intake is inadequate to support bone health.

Research Evidence / Overview of Studies for Teriparatide (Forsteo)

Evidence for use in Postmenopausal Osteoporosis

Research has examined the use of this drug in postmenopausal women through Randomized Controlled Trials (RCTs). These are studies where participants were randomly assigned to receive either the study drug or a placebo over a defined time interval. Studies monitored outcomes related to fracture occurrence (new vertebral and nonvertebral fractures) and changes in bone mineral density, which is a measurement of bone strength. This evidence contributes to understanding symptom patterns in populations where bone structure is weak.

The findings describe patterns observed in the studies over the treatment period, typically up to 24 months. These studies help show what has been observed so far regarding bone outcomes. However, the evidence is limited regarding the very long-term patterns of fracture outcomes after the defined treatment period ends. Follow-up durations were limited in many controlled trials, meaning that long-term effects are not fully established.

Evidence for use in Male Osteoporosis

The drug was evaluated in trials focused specifically on men diagnosed with primary or hypogonadal osteoporosis. These studies, which are often placebo-controlled, research examined how men responded to the treatment. The research focused on outcomes related to systemic or functional imbalance in bone turnover, mainly tracking changes in bone mineral density at specific skeletal sites.

The data show patterns related to measured changes in bone density compared to the placebo group during the study period. However, sample sizes were modest in some of the studies focusing solely on men. Consequently, data for certain groups remain insufficient to generalize the findings across all men with osteoporosis. Comparative evidence is lacking against all other available treatments for male osteoporosis.

Evidence in Special Populations and Uncertainty

The drug was studied for use in men and women whose osteoporosis was associated with the prolonged use of glucocorticoid medications (steroids), and the research describes the observed changes in measured bone density in this specific population. The drug was evaluated in general adult populations, but data for certain groups remain insufficient. For instance, there are limited studies examining the drug's use in the very elderly (e.g., those over 85) or in patients with significant kidney impairment.

Evidence highlights what is known—and what is still uncertain. Despite the availability of RCT data, certainty remains low in several areas. Comparative evidence is lacking for direct, head-to-head trials against all other bone-building treatments. The long-term effects are not fully established regarding safety beyond the 24-month treatment limit. Research does not determine whether an individual will respond similarly to the group averages observed in the trials.

Key Studies & References

1. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)
2. Update on the safety and efficacy of teriparatide in the treatment of osteoporosis

Storage and Disposal of Forsteo (teriparatide)

The storage and disposal of the Forsteo pre-filled pen must strictly follow regulatory mandates to ensure the stability of the solution.

Required Storage Conditions

• Mandatory Cold Chain: The pen must be stored in a refrigerator at all times, maintaining a temperature between 2 C to 8 C (36 F to 46 F). It is mandatory to return the pen to the refrigerator immediately after each use.
• Freezing and Integrity: Do not freeze Forsteo. If the medicine has been frozen, it must not be used and should be discarded. The solution must be clear and colorless; do not use it if it appears cloudy or contains particles.
• Container and Child Safety: The pen must not be stored with the needle attached. The medicine must be kept out of the sight and reach of children.

Shelf-Life and Disposal

• In-Use Period: Once first used, the pen has a maximum usable life of 28 days and must be discarded after this period, even if medicine remains.
• Needle Disposal: Used pen needles must be removed immediately and placed in a puncture-resistant sharps container.
• Final Disposal: Unused product and the expired 28-day pen must be disposed of in accordance with local pharmaceutical waste requirements.